Peptides Academy
Insulin Glargine
Lantus / Toujeo / Basaglar
Insulin glargine is a long-acting 'basal' analog insulin designed to provide steady background insulin over about a day. It is engineered in two ways: glycine replaces asparagine at position A21, and two arginine residues are added to the end of the B-chain. Together these changes shift the molecule's isoelectric point so that glargine is soluble in its slightly acidic injection solution but precipitates into tiny microcrystals when it reaches the neutral pH of subcutaneous tissue. Those microprecipitates then dissolve slowly, releasing insulin gradually and producing a long, relatively peakless action. The result is a once-daily (sometimes twice-daily) basal insulin that covers fasting and between-meal glucose, and is combined with rapid-acting mealtime insulin in basal-bolus therapy or used alone alongside other diabetes medicines in type 2 diabetes. A concentrated formulation, Toujeo (U-300), delivers the same insulin in a smaller volume with an even flatter, more prolonged profile; Basaglar and other products are biosimilar glargines that improved access. Glargine transformed basal insulin therapy by offering more predictable, longer coverage than NPH with generally less nocturnal hypoglycemia. It remains a prescription medicine whose central risk is hypoglycemia, and it is not interchangeable with mealtime insulins — injecting a basal insulin as if it were a rapid one, or vice versa, is dangerous. It is used under medical supervision and is not a wellness or performance product.
Specifications
| Dose Range | U-100 (Lantus/Basaglar); U-300 (Toujeo) |
| Origin / Manufacturer | Recombinant analog (A21 Gly, B-chain +2 Arg) |
| Regulatory Status | FDA-approvedEMA-approved |
| Active Components | Insulin glargine |
| Storage | Refrigerate unopened; in-use per label; do not freeze |
| Form Factor | Subcutaneous injection (pen/vial) |
Frequently Asked Questions
Reviewed by
Clinical Research Review Board
Pharmacology & Endocrinology Review
All clinical claims cross-checked against primary sources. Read our editorial policy →
Related Peptides
Insulin Degludec
Tresiba
An ultra-long-acting basal insulin: a fatty-acid tail makes it form long chains of multihexamers under the skin that release insulin very slowly, giving an exceptionally flat profile lasting well beyond 24 hours with flexible dosing timing.
Human Insulin (Regular / NPH)
Humulin / Novolin
The archetypal peptide-hormone medicine: a 51–amino-acid two-chain hormone that lowers blood glucose. Recombinant "human" insulin comes as short-acting Regular and intermediate-acting NPH, the backbone of insulin therapy for a century.
Insulin Icodec
Awiqli
A once-weekly basal insulin: strong, reversible binding to albumin plus a slowed receptor turnover give it a roughly seven-day half-life, so a single injection provides background insulin coverage for a whole week.
Insulin Lispro
Humalog / Admelog / Lyumjev
A rapid-acting analog insulin: swapping two B-chain amino acids stops the molecules from clumping, so it is absorbed and acts faster than human Regular insulin — designed to be taken right at mealtimes.